Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ersodetug - Rezolute

Next Previous
Search
Drug Profile

Ersodetug - Rezolute

Alternative Names: RZ-358; X 358; XOMA 247; XOMA 358; XPA.15.247

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XOMA
  • Developer Rezolute; XOMA
  • Class Antihypoglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital hyperinsulinism; Hypoglycaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Congenital hyperinsulinism
  • Phase II Hypoglycaemia

Most Recent Events

  • 18 Mar 2025 Rezolute plans a phase III trial for Hypoglycemia (Treatment-resistant) in April 2025 (NCT06881992)
  • 04 Feb 2025 Adverse events and pharmacokinetics data from a phase III sunRIZE trial in Congenital hyperinsulinism released by Rezolute
  • 07 Jan 2025 Ersodetug - Rezolute receives Breakthrough Therapy status for Hypoglycemia in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top